This is the single most important article on this site, and we have tried to write it so that you leave able to check the position yourself rather than having to trust us. The regulatory position on injectable fat dissolving in the United Kingdom is not complicated. It is just very rarely stated.
The position, stated plainly
A medicine sold in the United Kingdom for a particular purpose normally holds a marketing authorisation for that purpose, granted after a regulator has assessed evidence about its safety, its quality and whether it works. That assessment is the thing a patient is implicitly relying on when they use the word approved.
At the time of writing there is no product holding a United Kingdom marketing authorisation as a medicine for injectable fat dissolving. Practitioners offering the treatment are therefore using products outside any authorised indication for it. Some of those products are prescription only medicines, some are marketed in other ways, and the detail varies by product.
We are going to say something unusual here for a publication in this sector: do not take our word for this. Regulatory positions change, and a page dated last year is not a substitute for the current position. The MHRA is the body responsible, and asking a clinic to show you the regulatory status of the exact product they intend to inject is a reasonable request that a good clinic will answer without difficulty.
Why the licensing point actually matters
It is easy to hear unlicensed and file it as a technicality. It is not, and there are three practical consequences.
The first is the assessment itself. A licensing process is where evidence about safety and effectiveness for a specific use is examined by somebody with no commercial interest in the answer. Where that has not happened for the use in question, the ordinary safety net is not in place. This does not mean a product is dangerous. It means the question has not been answered by the body that normally answers it.
The second is what may be said. Where a product is a prescription only medicine, the Human Medicines Regulations 2012 restrict advertising it to the public. This is why the advertising you see for these treatments often avoids naming the substance and speaks instead in general terms about dissolving or contouring. Once you know why the language is vague, the vagueness becomes informative.
The third is redress. If a licensed medicine causes harm there are established routes, including reporting through the Yellow Card scheme, which patients may use directly. Where a product has been used outside an authorised indication, the position on liability and on who is responsible for correcting a poor outcome is less settled, and it becomes much more important that you know in advance what the clinic has committed to in writing.
“A safe, approved, non-surgical alternative to liposuction, with no downtime.”
What would have to be true
- That the product used holds an authorisation in the United Kingdom for this purpose, which the word approved implies to an ordinary reader.
- That the treatment achieves an effect of the same order as a surgical procedure, which alternative implies.
- That safety has been assessed and established for the specific product, at the dose and site used.
What is actually established
- The word approved has no fixed meaning in United Kingdom advertising and is understood by readers as a regulatory endorsement. Whether such an endorsement exists is a question of fact with a checkable answer.
- There is no licensed injectable fat dissolving medicine in the United Kingdom at the time of writing.
- Where a product is a prescription only medicine, promoting it to the public is restricted under the Human Medicines Regulations 2012.
This is not primarily a scientific dispute. It is a claim that positions an unlicensed use as an approved one, in a category where the ordinary reader has no way of checking. That is the reason this article exists, and it is why we would rather you verified the position yourself with the regulator than accepted our summary of it.
The prescriber question
Where the product used is a prescription only medicine, somebody has to prescribe it, and that somebody must be an appropriate prescriber. The question worth asking is not only who prescribed it but whether that person assessed you.
Remote prescribing, where a prescriber who has never met the patient authorises a prescription only medicine for them, is a recognised fault line across United Kingdom aesthetics. The professional standards of the healthcare regulators address prescribing generally, and a prescriber who has not assessed you is a position that is difficult to defend.
Practically: ask who prescribed the product, whether they will assess you in person, and what their registration number is. Registration numbers are checkable free on the public registers of the healthcare regulators. A clinic that treats these as intrusive questions has answered them.
Who injectable fat dissolving is a poor fit for
- Anyone who has not been told, in plain words, that the product being used is not licensed for this purpose in the United Kingdom. That disclosure is the minimum condition of consent here.
- Anyone who cannot get the product name, in writing, before the appointment. If you do not know what is being injected, you cannot look it up and you cannot report a reaction accurately.
- Anyone hoping for an effect comparable to surgery. It is a localised treatment for small deposits, not a volume procedure.
- Anyone with an infection at the site, a bleeding disorder, or who is pregnant or breastfeeding.
- Anyone who has not been told what happens if there is a complication, including who is clinically responsible out of hours and where they would be seen.
- Anyone being treated by somebody who cannot say who prescribed the product, if it is a prescription only medicine.
Wanting this treatment is entirely reasonable. Buying it without knowing the regulatory position is what we are asking you to avoid, because that position changes what the risk actually is.
What the treatment involves, described accurately
A series of small injections is placed into the fat layer of a defined area. The area swells, often considerably, and stays swollen for a period of days. Bruising, tenderness and firmness are usual. The treatment is generally uncomfortable during delivery and sore afterwards, and this is normal rather than a sign of a problem.
The treated area is small. This is a treatment for defined localised deposits, of the kind that persist in otherwise stable people, and multiple sessions are usual because the amount that can be treated at once is limited. It is not a volume procedure and framing it as an alternative to surgery is a claim about scale that it cannot support.
We describe the mechanism itself in detail in what deoxycholic acid does in tissue.
Risks worth naming
Expected effects include swelling, bruising, tenderness, firmness and numbness. Less common but recognised problems include nodules, irregularity or dents in the treated area, prolonged swelling, and injury to structures near the injection site. Injecting a substance that damages fat cells into an area also means it can damage other tissue it reaches, which is why the anatomical knowledge of the injector matters and why site selection is not a cosmetic decision.
Infection is a recognised risk of any injection. A clinic should be able to tell you how they would recognise one, who you would contact, and how quickly. If the answer to any of those is a message on social media the following week, that is your answer about the clinic.
You can report a suspected adverse reaction yourself through the Yellow Card scheme. You do not need the clinic's permission and you do not need to be certain the product caused it.
There is no maintenance dependency in the way there is with device courses, because if fat cells are destroyed they do not return. What is not fixed is your body's response over time, since the fat cells that remain still change size with weight. Clinics often recommend further sessions, and the reason is usually coverage rather than maintenance: one session treats a limited amount of tissue.
What to do with this, practically
If you are considering this treatment, the sequence we would suggest is straightforward. Get the product name in writing before you book. Check the current regulatory position for that product with the MHRA rather than with the clinic. Ask who prescribes it, whether they will assess you in person, and what their registration number is. Ask what the clinic's written policy is if there is a complication or an unsatisfactory result, and get it in writing before paying a deposit. Ask what would make them decline to treat you.
None of these are aggressive questions. They are the questions a well run clinic expects, and the reaction to them is the most useful diagnostic available to you. We have collected the full set in the questions to ask before you pay.
The wider regulatory picture
It is worth knowing that the general regulatory framework around non-surgical cosmetic procedures in England is incomplete. Section 180 of the Health and Care Act 2022 created a power to establish a licensing scheme for procedures of this kind. A power is not a scheme, and at the time of writing no such scheme is in force. We cover that in detail in the licensing power and why it is not in force.
Until it is, the practical position is that the checks are yours to make. That is not a satisfactory arrangement and it is the arrangement that exists.